Iqirvo® (elafibranor) - Global
Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Media  arrow down
    < Back
    • Press Releases
    • Media Statements
    • Media Library

    • Our 2023 Integrated Annual Report is live!

       Featured Image
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports and Accounts
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Shareholder Information
    • Regulated Information
    • Key Contacts
  • Partnering
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
  • Home
  • Companyarrow down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow down
      < Back
    • Science
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
    • Lay Summaries
  • Sustainabilityarrow down
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patientsarrow down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
Back

Post navigation

Previous

Iqirvo® (elafibranor)

Iqirvo® (elafibranor)

- 13 March 2025 - 0 mins read

Post navigation

Previous

Related Products

Tazverik<sup>®</sup> (tazemetostat)
28 April 2023 0 mins read

Tazverik® (tazemetostat)
Somatuline<sup>®</sup> (lanreotide acetate)
28 April 2023 0 mins read

Somatuline® (lanreotide acetate)
Sohonos<sup>®</sup> (palovarotene)
28 April 2023 0 mins read

Sohonos® (palovarotene)
Onivyde<sup>®</sup> (irinotecan liposome injection)
28 April 2023 0 mins read

Onivyde® (irinotecan liposome injection)
Dysport<sup>®</sup> (abobotulinumtoxinA)
28 April 2023 0 mins read

Dysport® (abobotulinumtoxinA)
Decapeptyl<sup>®</sup> (triptorelin pamoate or acetate)
28 April 2023 0 mins read

Decapeptyl® (triptorelin pamoate or acetate)
Cometriq<sup>®</sup> (cabozantinib)
28 April 2023 0 mins read

Cometriq® (cabozantinib)
Bylvay<sup>®</sup> (odevixibat)
28 April 2023 0 mins read

Bylvay® (odevixibat)
Cabometyx<sup>®</sup> (cabozantinib)
18 April 2023 0 mins read

Cabometyx® (cabozantinib)

IPN price

€102.10

 €2.15 (2.15%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Sustainability
  • Patients
  • Stories
  • Annual Report
  • Contact us
Latest_Ipsen logo
LinkedIn Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2025

You are now leaving the Ipsen group website. To continue, please click on Continue?

Continue